Clomiphene QB
Related Articles
Venky’s (India) rose 5.48% to Rs 2,735.30 after the company announced that it was establishing a new project to manufacture veterinary medicine products as part of its animal health products segment.
The company has acquired 15,030 square meters of land in Satara in Maharashtra for this purpose. The project is expected to be completed by March 2022 and commercial production will start from June 2022.
In an exchange brief, the company said this project will focus on manufacturing veterinary drug powders (600 tons / year) and veterinary drug liquids (300 kiloliters / year) to meet growing demand from the world. poultry industry.
The total cost of the project is estimated at Rs 30 crore, which will be funded from internal provisions.
The proposed plant will be the company’s second and will comply with the latest FDA regulations and is expected to meet export needs as well.
Venky’s already has a factory in Pune (Maharashtra) with a capacity of 600 tonnes / year and this capacity is 70-80% used.
Venky (India) net profit decreased 15.6% to Rs 30.68 crore on a 40.7% increase in operating income to Rs 987.76 crore in Q2 FY22 compared to Q2 FY21.
Venky’s (India) is part of the VH group which is the largest and most integrated poultry player in India. The company’s diverse product line includes SPF eggs, chicken and egg processing, broiler and layer breeding, genetic research and poultry disease diagnostics, vaccines and dietary supplements for poultry, vaccine production, biosecurity products, poultry feed and equipment, nutritional health products, soy bean extract, etc.
Powered by Capital Market – Live News
(This story was not edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear reader,
Business Standard has always strived to provide up-to-date information and commentary on developments that matter to you and have broader political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even in these difficult times resulting from Covid-19, we remain committed to keeping you informed and updated with credible news, authoritative views and cutting-edge commentary on relevant current issues.
However, we have a demand.
As we fight the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. More subscriptions to our online content can only help us achieve the goals of providing you with even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practice the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital editor
